Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
2017 · Nature Medicine · 3,415 citations
https://doi.org/10.1038/nm.4333
M
Mark E. Robson
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
952
Papers
58.4K
Citations
115
h-index
395
i10-index
Mark E. Robson is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: BRCA gene mutations in cancer & Cancer Genomics and Diagnostics & Genetic factors in colorectal cancer. The author has an h-index of 115, co-authored 810 publications.
ORCID: 0000-0002-3109-1692Papers by this author
worksOlaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation
2017 · New England Journal of Medicine · 3,073 citations
https://doi.org/10.1056/nejmoa1706450
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
2016 · New England Journal of Medicine · 1,630 citations
https://doi.org/10.1056/nejmoa1603144
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
2010 · The Lancet · 1,625 citations
https://doi.org/10.1016/s0140-6736(10)60892-6
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
2018 · The American Journal of Human Genetics · 1,152 citations
https://doi.org/10.1016/j.ajhg.2018.11.002
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
2019 · Annals of Oncology · 736 citations
https://doi.org/10.1093/annonc/mdz012
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat